4 Generations of Knowledge
3 Decades of Investing in Innovation
We Help Entrepreneurs Build Market Leaders

Focused on Early Stage IT and Healthcare Investments

A Network of 400 Companies and 4,000 Executives

Play Video

USVP IN NUMBERS

$3.9B

Total Invested

498

Companies

89

IPOs

NEWS

Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
July 28, 2020

Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Business WirePress
Epsagon Increases Total Fundraising to $30M to Become the Leading Applied Observability Platform Across Microservices Environments
July 21, 2020

Epsagon Increases Total Fundraising to $30M to Become the Leading Applied Observability Platform Across Microservices Environments

Epsagon Increases Total Fundraising to $30M to Become the Leading Applied Observability Platform Across Microservices Environments
DTCPPress
Announcing USVP XII
February 3, 2020

Announcing USVP XII

Announcing USVP XII
Business WirePress